Description
Rivaroxaban is an orally bioavailable oxazolidone derivative that acts as an antithrombotic/anticoagulant, reversibly inhibiting factor Xa. Rivaroxaban directly binds to the S1 and S4 pockets of factor Xa and inhibits both free and clot-bound forms. In vitro models indicate that rivaroxaban may also exert inhibitory effects during the early stages of bone formation, as it inhibits hormone-stimulated modulation of ER and 1-OHase expression as well as DNA synthesis, creatine kinase activity, and alkaline phosphatase activity.